Show Nav →

Overview Data source: UniProt

Official Gene Symbol Other Aliases
GLYR1 HIBDL, NP60
Sequence Length (AA) Molecular Weight (Da)
553 60556
Protein Name
Putative oxidoreductase GLYR1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MAAVSLRLGD LVWGKLGRYP PWPGKIVNPP KDLKKPRGKK CFFVKFFGTE
60 70 80 90 100
DHAWIKVEQL KPYHAHKEEM IKINKGKRFQ QAVDAVEEFL RRAKGKDQTS
110 120 130 140 150
SHNSSDDKNR RNSSEERSRP NSGDEKRKLS LSEGKVKKNM GEGKKRVSSG
160 170 180 190 200
SSERGSKSPL KRAQEQSPRK RGRPPKDEKD LTIPESSTVK GMMAGPMAAF
210 220 230 240 250
KWQPTASEPV KDADPHFHHF LLSQTEKPAV CYQAITKKLK ICEEETGSTS
260 270 280 290 300
IQAADSTAVN GSITPTDKKI GFLGLGLMGS GIVSNLLKMG HTVTVWNRTA
310 320 330 340 350
EKCDLFIQEG ARLGRTPAEV VSTCDITFAC VSDPKAAKDL VLGPSGVLQG
360 370 380 390 400
IRPGKCYVDM STVDADTVTE LAQVIVSRGG RFLEAPVSGN QQLSNDGMLV
410 420 430 440 450
ILAAGDRGLY EDCSSCFQAM GKTSFFLGEV GNAAKMMLIV NMVQGSFMAT
460 470 480 490 500
IAEGLTLAHV TGQSQQTLLD ILNQGQLASI FLDQKCQNIL QGNFKPDFYL
510 520 530 540 550
KYIQKDLRLA IALGDAVNHP TPMAAAANEV YKRAKALDQS DNDMSAVYRA
553
YIH

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-1348 Collapse assay details

Data source: Panorama

Official Gene Symbol
GLYR1
Peptide Modified Sequence
KLS[+80.0]LSEGK
Modification Type
Phospho (ST)
Protein - Site of Modification
130
Peptide - Site of Modification
3
Peptide Start
128
Peptide End
135
CPTAC ID
CPTAC-1348
Peptide Molecular Mass
940.4631
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
Fe(III)-NTA
Matrix
digested cell lysate
Submitting Laboratory
Broad Institute
Submitting Lab PI
Steven A. Carr

Publication

View Details (opens in a new window)

Mol Cell Proteomics. 2016 May;15(5):1622-41. doi: 10.1074/mcp.M116.058354. Epub 2016 Feb 24. Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes. Abelin JG1, Patel J1, Lu X1, Feeney CM1, Fagbami L1, Creech AL1, Hu R1, Lam D1, Davison D1, Pino L1, Qiao JW1, Kuhn E1, Officer A1, Li J2, Abbatiello S1, Subramanian A1, Sidman R2, Snyder E3, Carr SA1, Jaffe JD4.

View Details (opens in a new window)

Mol Cell Proteomics. 2014 Jul;13(7):1690-704. doi: 10.1074/mcp.M113.036392. Epub 2014 Apr 9. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mertins P1, Yang F2, Liu T2, Mani DR3, Petyuk VA2, Gillette MA3, Clauser KR3, Qiao JW3, Gritsenko MA2, Moore RJ2, Levine DA4, Townsend R5, Erdmann-Gilmore P5, Snider JE5, Davies SR5, Ruggles KV6, Fenyo D6, Kitchens RT5, Li S5, Olvera N4, Dao F4, Rodriguez H7, Chan DW8, Liebler D9, White F10, Rodland KD2, Mills GB11, Smith RD2, Paulovich AG12, Ellis M5, Carr SA1


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Quantiva
Internal Standard
light stable isotope peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Easy NanoLC1000
Column Packing
Reprosil C18, 1.9um, 200A
Column Dimensions
0.075 x 150 mm
Flow Rate
200 nL/min

Assay Multiplexing Expand assay panel

Broad Institute-Stress Pathway Panel


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y4 (1+) 4.2 4.6 6.5 7.9 9.7 11.4 8.9 10.7 13.1 15 15 15
y6-98 (1+) 5 6.4 6.1 7.5 9.5 11.4 9 11.5 12.9 15 15 15
y7-98 (1+) 5.2 6.6 6.3 7 10.5 11.2 8.7 12.4 12.9 15 15 15
sum 4.4 5.8 5.5 6.9 9.6 10.9 8.2 11.2 12.2 15 15 15

Additional Resources and Comments